Assembly Biosciences

About Assembly Assembly Biosciences, Inc. is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's proprietary Core Protein Allosteric Modulators (CpAMs) are small molecule, oral agents for the treatment of viral infections. The company's lead program focuses on hepatitis B (HBV), which infects an estimated 350 million people worldwide and is associated with 600,000 deaths annually. CpAMs alter the HBV core protein, a unique target that is essential to the functioning of the virus. Unlike current therapies that only suppress HBV, CpAMs may have curative potential. Assembly also is developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections.
Company Growth (employees)
New York, US
Size (employees)
51 (est)
Assembly Biosciences was founded in 2007 and is headquartered in New York, US

Assembly Biosciences Office Locations

Assembly Biosciences has offices in New York, Carmel, Bloomington, San Francisco
New York, US
San Francisco, US
Bloomington, US
Carmel, US

Assembly Biosciences Metrics

Assembly Biosciences Summary

Market capitalization

$430.2 m

Closing share price

Assembly Biosciences's current market capitalization is $430.2 m.

Assembly Biosciences Market Value History

We estimate that Assembly Biosciences's current employees are approximately 16% female and 84% male.

Assembly Biosciences Company Life

You may also be interested in